Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIAS: I-VRD vs ASCT in Low-Risk NDMM
NCT05665140Phase 3Recruiting
- Sponsor
- University Hospital Schleswig-Holstein Campus Lübeck
- Start
- Feb 2023
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM), sponsored by University Hospital Schleswig-Holstein Campus Lübeck. Started Feb 2023; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05665140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665140.